Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Mark J. Robinson

Partner
 
Mark Robinson has over 25 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.

Mr. Robinson joined Centerview in 2009 to establish its healthcare practice after 12 years at Merrill Lynch, serving as the Global Co-Head of Healthcare Investment Banking for the last six years.

Selected advisory assignments while at Centerview include:
• Immunomedics on its $21.0 billion acquisition by Gilead
• Pharmacyclics on its $21.0 billion sale to Abbvie
• MyoKardia on its $13.1 billion acquisition by Bristol Myers Squibb
• Array Biopharma on its $11.8 billion sale to Pfizer
• Onyx on its $10.4 billion sale to Amgen
• InterMune on its $8.9 billion sale to Roche
• AveXis on its $8.7 billion sale to Novartis
• Receptos on its $7.8 billion sale to Celgene
• Momenta on its $6.5 billion acquisition by Johnson & Johnson
• Auris Health on its sale for up to $5.8 billion to Johnson & Johnson
• Tesaro on its $5.1 billion sale to GlaxoSmithKline
• Forty-Seven on its $4.9 billion sale to Gilead
• Spark on its $4.8 billion sale to Roche
• OSI on its hostile defense and $4.0 billion sale to Astellas
• Idenix on its $3.8 billion sale to Merck
• Avanir on its $3.5 billion sale to Otsuka
• Audentes on its $3.0 billion sale to Astellas
• Alder BioPharmaceuticals on its $2.0 billion sale to Lundbeck
• Tobira on its sale for up to $1.7 billion to Allergan
• Portola on its $1.6 billion sale to Alexion
• Relypsa on its $1.5 billion sale to Galenica

Notable transactions at Merrill Lynch include advising Immunex in its $16 billion sale to Amgen, IDEC in its $7 billion merger with Biogen to create Biogen Idec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa. From the beginning of his career in 1993, until he left Merrill Lynch, Mr. Robinson was a leading advisor in raising capital for companies in the biotechnology and medical device industries.

He earned a B.A. from the University of California Berkeley and an M.B.A. from Harvard Business School. Mr. Robinson serves on the Board of the College of Letters and Science at U.C. Berkeley and is a member of both the Board of Trustees of the U.C. Berkeley Foundation and The Thacher School, as well as a member of the Council on Foreign Relations.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Engie SA
Announced: Q4 2020
Value: €3.4 billion

Advisor to the board of Engie on the disposal of its 29.9% stake in Suez
View All
New York

Centerview Partners LLC


31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax
London

Centerview Partners UK LLP


100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax
Paris

Centerview Partners France SCS


16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC


600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC


555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax





Chicago

Centerview Partners LLC





Los Angeles

Centerview Partners LLC





Copyright © 2008 - 2020 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC